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Particle therapya b s t r a c t
Background and Purpose: In this multicentric in silico trial we compared photon, proton, and carbon-ion
radiotherapy plans for re-irradiation of patients with squamous cell carcinoma of the head and neck
(HNSCC) regarding dose to tumour and doses to surrounding organs at risk (OARs).
Material and Methods: Twenty-five HNSCC patients with a second new or recurrent cancer after previous
irradiation (70 Gy) were included. Intensity-modulated proton therapy (IMPT) and ion therapy (IMIT) re-
irradiation plans to a second subsequent dose of 70 Gy were compared to photon therapy delivered with
volumetric modulated arc therapy (VMAT).
Results: When comparing IMIT and IMPT to VMAT, the mean dose to all investigated 22 OARs was signif-
icantly reduced for IMIT and to 15 out of 22 OARs (68%) using IMPT. The maximum dose to 2% volume
(D2) of the brainstem and spinal cord were significantly reduced using IMPT and IMIT compared to
VMAT. The data are available on www.cancerdata.org.
Conclusions: In this ROCOCO in silico trial, a reduction in mean dose to OARs was achieved using particle
therapy compared to photons in the re-irradiation of HNSCC. There was a dosimetric benefit favouring
carbon-ions above proton therapy. These dose reductions may potentially translate into lower severe
complication rates related to the re-irradiation.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 121 (2016) 387–394
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Squamous cell carcinoma of the head and neck (HNSCC) is the
sixth most prevalent cancer in the world and is still considered dif-
ficult to cure [1,2]. In addition to the abuse of alcohol and/or
tobacco, infection with human papilloma virus (HPV) is a risk
factor.
Despite many new treatment options, the risk of local or regio-
nal recurrence for patients with HNSCC having undergone (chemo)
radiotherapy or tri-modality treatment is still up to 30% [3–5].
Additionally, the estimated 5-year cumulative incidence of second
new tumours was 13% in the radiotherapy group and 12% in the
combined therapy group according to Bernier et al. [6]. The treat-
ment of locoregional recurrence of HNSCC consists of surgical
resection with or without adjuvant (chemo)radiation or primarydefinitive (chemo)radiation, leading to an overall 5-year relative
survival rate of 40–66% in selected patients [1].
In case of an unresectable recurrence, re-irradiation (re-RT) pos-
sibly combined with systemic therapy, is an alternative curative
option. In the postoperative setting, re-RT should be considered if
features in the pathology specimen, such a positive resection
margin or extracapsular extension, indicate high risk of recurrence
[7–10]. Long-term disease control and survival can be achieved in
patients who receive re-RT as an adjunct to surgical resection.
However, the rates of severe grade 3 or 4 toxicity after re-RT are
high, with an incidence of approximately 45% at 5 years, and only
approximately 1 in 3 patients survives re-RT without recurrence
and severe complications [11]. Reduction of the risk of radiation-
induced complications and improvement of the oncological
outcome are needed [8,12–14,10,15,16].
In recent years, there has been enormous progress in radiother-
apy techniques, moving from 3D conformal radiotherapy (3D-CRT)
388 Re-irradiating HNSCC: benefit of PTto intensity-modulated radiotherapy (IMRT) and volumetric mod-
ulated arc therapy (VMAT), enabling highly conformal treatment
with dose reductions to healthy tissue and surrounding organs at
risk (OARs) [17,18]. Still the OARs and healthy tissues frequently
receive a significant dose with 3D-CRT and IMRT [18,19].
Particle therapy (PT) is becoming increasingly available, which
prompts interest amongphysicians aswell as health insurance com-
panies regarding its efficacy in HNSCC. To assess the potential gains
of PT for individual patients in the re-irradiation setting, we con-
ducted an in silico treatment planning study on a cohort of 25HNSCC
patients retrospectively retrieved from two Dutch radiotherapy
departments. Data are available on www.cancerdata.org [20].Methods
Study population
We retrospectively retrieved treatment plans of HNSCC patients
stage I to IVB who had undergone (chemo)radiotherapy with cura-
tive intent (P50 Gy, including at least lymph node levels II-IV) at
Radboud University Medical Centre (UMC) or at MAASTRO clinic
and who were subsequently (>1 year later) re-irradiated (with or
without surgery and/or chemotherapy), with a relevant overlap
of the target volume (clinicaltrial.gov ID: NCT 02242916).Target volume and OAR definition
An individual neck support and head fixation were used in all
patients. For treatment planning purposes, computed tomography
(CT) images with intravenous contrast were used. The gross
tumour volume (GTV) was delineated as the macroscopic tumour
on the planning-CT fused with the hybrid fluorodeoxyglucose posi-
tron emission tomography (FDG-PET) and/or after rigid mutual-
information-based registration with magnetic resonance imaging
(MRI). The GTV and the clinical target volume (CTV) were delin-
eated using local guidelines (RadboudUMC or MAASTRO clinic)
based on Gregoire et al. [21–23]. The CTV was expanded to the
planning target volume (PTV) taking into account the individual
institutions’ margin recipe: VMAT utilised 4 mm accounting for
setup errors, intensity-modulated ion therapy (IMIT) employed
4 mm and intensity-modulated proton therapy (IMPT) 5 mm and
3 mm for the boost to the high risk PTV, to account for both setup
and range uncertainties. The low risk volume, PTV with a pre-
scribed dose of 54 Gy (PTV54Gy), consisted of the tumour or tumour
bed, the pathological lymph nodes and the elective lymph node
levels. The high risk PTV planned to a total dose of 70 Gy (PTV70Gy)
was defined as the tumour or tumour bed and/or pathological
lymph nodes. For all 25 patients included in this in silico study,
the OARs were outlined by one dosimetrist (M.G.) and supervised
by a radiation oncologist (D.E.) for the first and re-RT study set
(see Table 1 for the list of OARs). Dental fillings and associated arte-
facts were delineated and the density was overridden to that of
teeth or tissue, respectively, for dental fillings within the treatment
beam were an exclusion criterion for PT. The use of any form of
bolus to assure an accurate coverage of the target volume was per-
mitted. There was no correction for the use of intravenous contrast.Treatment planning
The first treatment was considered a precondition in all
patients, determining the remaining tolerance dose for the OARs,
and therefore not described here. All subsequent paragraphs relate
to the re-RT treatment plans. The PTV54Gy was irradiated to a total
dose of 54.25 Gy in 35 fractions of 1.55 Gy, the PTV70Gy to 70 Gy in
35 fractions of 2 Gy using a simultaneous integrated boost (SIB)
technique. In case no elective lymph nodes were included, 70 Gywas prescribed in 35 fractions of 2 Gy to PTV70Gy (the tumour or
pathological lymph node only).
All proton and photon treatment plans were calculated in cen-
tres that were already operating and had significant clinical expe-
rience in treatment planning. The prescribed dose to the PTV70Gy
was set to 70 Gy of which 99% of the volume had to be covered
by 95% of the dose for all modalities in order to enable a direct
comparison. All plans were evaluated for robustness.Dose constraints
For the OARs, the dose limits and priorities were defined in the
protocol (Table 1). The dose–volume histograms (DVHs) of the orig-
inal treatment planswere used to calculate the re-RT constraints for
four OARs: the brainstem, spinal cord, mandible and larynx (includ-
ing arytenoid). Since there was an interval ofP1 year between first
and second treatment, a 30% recovery was assumed for these four
OARs [35–37]. The locations of the maximum dose (Dmax) within
an OAR in the first and secondary treatment plans were assumed
to be the same, as a worst-case scenario, since the average overlap
of the second treatment volume with the first treatment volume
was determined to be 67%. No correction for fraction size was per-
formed. Parotid and submandibular glands, if preserved in the first
treatment, were attempted to be spared with second and third pri-
ority, respectively, without being dose limiting. For larynx, ary-
tenoids and mandible, cumulative dose, which was the sum of the
first and second treatment, was considered only dose limiting if
the OAR was not part of the CTV in the first and second treatment
(see Table 1). Attempts were made to minimise dose to the base of
tongue, carotid arteries, jugular veins, oral cavity, sternocleidomas-
toid muscles, swallowing muscles, thyroid and vertebrae, but these
structures were not dose limiting. For each re-RT plan, the mean
dose (Dmean) was calculated per OAR as well as the near-maximum
dose, defined as the highest dose to 2% of the volume (D2), and the
near-minimumdose definedas the lowest dose to 98%of the volume
(D98) [38]. Themean integral dose (ID)was defined as themeandose
to the imaged part of the patient (body contour) minus CTV, also
known as the residual volume at risk (RVR).Photons
The original clinically applied re-RT treatment plans were cre-
ated at RadboudUMC using Pinnacle (Pinnacle v8.2g Philips, WI)
and at MAASTRO clinic using Varian (EclipseTM v11.0 Varian Medi-
cal Systems, Palo Alto, CA). In order to account for improvements
in photon plan techniques over the past years, the actual re-RT
photon treatment plans were re-calculated employing state-of-
the-art VMAT planning at MAASTRO clinic. With regard to VMAT,
photons were considered to be innately robust relative to PT,
therefore no explicit optimisation techniques were incorporated
into the VMAT plans as the PTV was assumed to be sufficient to
produce a robust plan.Protons
Proton re-treatment plans were calculated at University of
Pennsylvania (UPENN) using IMPT for beam delivery with pencil
beam scanning (PBS) (EclipseTM v11.0 Varian Medical Systems)
using beam data modelled for IBA universal nozzle on a gantry
(Ion Beam Applications, Louvain-la-Neuve, Belgium) [24]. Multi-
field optimisation (MFO) was used in the planning process as it
produced superior OAR sparing compared to a single field uniform
dose (SFO) approach [25]. To preserve small spots, UPENN utilised
a universal bolus instead of a more conventional range shifter for
the treatment of head and neck tumours [26]. A relative biological
effectiveness (RBE) of 1.1 was used [27]. A typical field
Table 1
Dose constraints and priorities for organs at risk. The tolerance dose per OAR for the first and second treatment in Gy (E) with their planning priority.
OAR First treatment Second treatment
Tolerance Tolerance Priority
Brain Stem Dmax 54 Gy Individuala 1
Spinal cord Dmax 50 Gy Individuala 1
Larynx Dmax 45 Gy 120 Gyb 1
Arytenoid Dmax 50 Gy 100 Gyb 1
Mandible Dmax 60 Gy 120 Gyb 1
Parotid glands (spared) Dmean 26 Gy No limit 2
Submandibular glands (spared) Dmean 26 Gy No limit 3
Swallowing muscle Dmax 50 Gy No limit 4
Carotid artery Dmax 50 Gy No limit 5
Jugular artery Dmax 50 Gy No limit 5
Oral cavity Dmean 26 Gy No limit 5
Sternocleidomastoid muscle Dmax 60 Gy No limit 5
Thyroid Dmax 60 Gy No limit 5
Vertebrae Dmax 60 Gy No limit 5
Dose limiting, exceeding this dose is not permitted.
Only dose limiting if the OAR was not part of the CTV in the first and second treatment.
Kept as low as possible if OAR was spared in the first treatment, not dose limiting.
Goal limits, not dose limiting.
OAR = organs at risk, Dmax = maximum dose, Dmean = mean dose.
a For each individual patient calculated assuming 30% recovery from first treatment.
b Cumulative dose, the sum of the first and second treatment.
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rior and posterior oblique beam, depending on target geometry. A
lateral field was added or substituted for one posterior oblique
when the Dmax spinal cord constraint could not be met due to high
dose target structures crossing the midline distal to the cord. PT is,
with regard to IMPT, known to be intrinsically non-robust, there-
fore a PTV with a margin of 3 mm from the CTV was created with
an additional 2 mm added to the planning optimisation volume to
account for range uncertainty. The 5 mm margin is a conservative
value for head and neck assuming an overall uncertainty of 3.5% in
conversion from Hounsfield Unit (HU) to relative proton stopping
power and a range of approximately 15 cm [28,29]. The following
margin definition in head and head-and-neck boost treatments
was used: 3 mm transversal to the beam (on account of the resid-
ual patient positioning error, robotic table/imager uncertainties
and beam steering) and 3 mm along the beam on account of the
range uncertainties assuming HU calibration accuracy of 3% and
beam range of ca. 10 cm [30,31].Carbon ions
Carbon ion (C-ion) re-RT treatment plans were calculated at
University of Marburg using a raster scanning technique with
intensity-modulated ion therapy (IMIT) using Syngo PT Planning
(Siemens Health Care Systems, Erlangen, Germany), which
employed the local effect model (LEM1) for the biologically
weighted dose computation [32,33]. The number of fields varied
from 1 (in 1 case) to 3 (in 3 cases).The beam directions (using
isocentric table rotations and gantry when deemed advantageous)
were chosen individually for each case with two main considera-
tions: avoidance of any unnecessary dose and evading strong den-
sity heterogeneities in the beam entrance channels [34].
Furthermore, beam directions traversing patient support and
immobilisation devices were avoided. For multiple beam setups
reduced the under-dosages caused by potential range uncertain-
ties, a uniform margin of 4 mm was applied with a tolerance of
2 mm, allowing the TPS to place additional raster spots outside
the PTV as necessary, thus ensuring target coverage.Plan robustness evaluation
All treatment plans (VMAT, IMPT, and IMIT) were assessed for
robustness of the CTV coverage in their respective centres of origin.The robustness of the treatment plans was evaluated using worst-
case scenario plan calculations with a ± 3 mm isocenter shift in x-,
y-, and z-directions combined with a ± 3.5% density shift (12 com-
binations per plan). The minimal dose to 95% and 98% of the CTV is
given (D95 and D98), respectively.Storage of imaging datasets
The datasets were stored and exchanged through the secured
collaborative MISTIR platform (www.mistir.info) hosted by MAAS-
TRO clinic. Quality assurance procedures were applied to assess the
necessity of corrections of transformations during treatment plan-
ning system (TPS) import and export [39].Data evaluation and statistical analysis
Matlab software (The Math Works, Natick, MA) was used for
statistical analysis. The dose matrices were scaled to the mean
CTV70Gy doses of 70 Gy (RBE equivalent) as this structure did not
change between modalities. The dose metrics were extracted from
the plan and statistically compared using two-tailed, signed-rank
Wilcoxon tests to determine the significance of pairwise differ-
ences compared to VMAT (a p-value of <0.02 was considered sig-
nificant, taking a Bonferroni correction into account).Results
Twenty-five cases were included and in total 75 re-RT plans
were analysed; one example is illustrated in Fig. 1. All treatment
modalities achieved a comparable dose to the CTV54Gy and CTV70Gy
(Table 2). All plans were judged to be clinically applicable with
worst-case scenario CTV robustness tests resulting in
D98 = 95.4 ± 1.9% and D95 = 97.9 ± 1.4% for VMAT, D98 = 94.6 ± 2.8%
and D95 = 96.2 ± 2.4% for IMPT, and D98 = 93.1 ± 3.0 and
D95 = 96.1 ± 1.8 for IMIT (see Supplementary Table I).
The average scaled values of the Dmean and D2 for the OARs were
compared between VMAT and IMPT/IMIT (Table 2, dose signifi-
cance indicated with an asterisk). When comparing IMIT and IMPT
to VMAT, the Dmean to all 22 OARs was statistically significantly
reduced for IMIT and to 15 out of 22 OARs (68%) using IMPT
(p < 0.02). The D2 for the brainstem and spinal cord was statisti-
cally significantly reduced (p < 0.02) using IMPT and IMIT
Fig. 1. A set of re-irradiation treatment plans for a patient with a nodal recurrence of oropharynx carcinoma of the right tonsillar fossa, rcT0N2aM0. In the VMAT (left column),
IMPT (middle column) and IMIT (right column) plans, the CTV54Gy (pink) and high-dose CTV70Gy (orange). The dose-range is presented from high (red) to low (blue).
Table 2
Mean doses (SD) of selected dosimetric parameters for organs at risk and target volume in Gy(E) for IMPT and IMIT compared to VMAT after scaling to the mean CTV70 Gy doses
of 70 Gy.
Dmean (Gy) VMAT IMPT IMIT
Arytenoid ipsi & bilateral 34.5 (24.4) 27.3 (24.9) 20.6 (24.9)a
Arytenoid contralateral 17.6 (13.2) 2.3 (4.2)a 1.1 (0.9)a
Base of tongue 32.1 (19.4) 25.5 (23.3) 18.8 (21.7)a
Carotid ipsi- & bilateral 35.0 (17.1) 35.9 (19.4) 31.9 (19.8)a
Carotid contralateral 12.9 (8.4) 2.0 (4.5)a 0.83 (1.4)a
Body 5.9 (2.8) 3.9 (2.1)a 2.7 (1.5)a
Jugular ipsi- & bilateral 29.6 (20.2) 29.0 (22.5) 24.6 (22.8)a
Jugular contralateral 10.4 (6.6) 0.97 (3.0)a 0.57 (1.6)a
Larynx 34.1 (18.0) 27.2 (18.4)a 20.3 (17.5)a
Mandible 16.1 (12.7) 11.5 (11.5)a 8.2 (11.0)a
Oral cavity 14.9 (14.3) 9.0 (13.7)a 7.6 (14.6)a
Parotid ipsi- & bilateral 16.0 (15.2) 16.3 (16.6) 13.5 (14.5)a
Parotid contralateral 4.4 (2.1) <0.01 (0.02)a 0.038 (0.13)a
Sterno cleido mastoid ipsi- & bilateral 31.2 (17.1) 30.9 (20.5) 26.3 (19.5)a
Sterno cleido mastoid contralateral 11.4 (6.8) 1.6 (3.0)a 0.64 (1.4)a
Submandibular gland ipsi- & bilateral 35.4 (20.0) 35.9 (20.2) 29.2 (18.5)a
Submandibular gland contralateral 16.3 (9.3) 0.64 (1.7)a 0.73 (1.2)a
Swallowing muscle total 31.9 (21.5) 25.1 (21.5)a 18.9 (21.1)a
Thyroid 30.9 (25.2) 29.8 (25.2) 25.9 (24.4)a
Vertebrae 18.1 (7.6) 10.8 (6.8)a 5.8 (4.2)a
CTV54Gy 60.9 (2.7) 61.7 (2.7)a 61.3 (2.5)
CTV70Gy 70.0 (<0.01) 70.0 (<0.01) 70.0 (<0.01)
D2 (Gy) VMAT IMPT IMIT
Brainstem 8.2 (7.9) 2.7 (5.3)a 1.3 (2.5)a
Spinal cord 16.6 (4.7) 6.7 (5.7)a 4.8 (3.2)a
V95 (%) VMAT IMPT IMIT
CTV54Gy 99.5 (0.6) 99.7 (0.4) 100.0 (0.02)a
CTV70Gy 98.9 (2.5) 99.9 (0.3) 99.9 (0.2)
a Is significant (P < 0.02).
390 Re-irradiating HNSCC: benefit of PTcompared to VMAT. The integral dose was highest for VMAT
(5.9 Gy), followed by IMPT (3.9 Gy) and IMIT (2.7 Gy).
IMPT and IMIT proved to be superior to VMAT in sparing the
contralateral located OARs. Depending on the OAR, this dosereduction was up to 85–100% for the contralateral carotid artery
and parotid gland, respectively, when using IMPT and 94–99% for
the contralateral carotid artery and parotid gland, respectively,
when using IMIT. Conversely, IMPT increased the ipsilateral dose
Fig. 2. The overall average mean dose [Dmean; a)] and maximum dose in Gy (equivalent) to 2% [D2, b)] for all OARs is given for volumetric modulated arc therapy (VMAT, blue),
intensity-modulated proton therapy (IMPT, red) and intensity-modulated ion therapy (IMIT, green). (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
Fig. 3. Percentage of patients receiving lower dose to the organs at risk when applying IMPT and/or IMIT compared to VMAT. The maximum dose received by 2% of that
specific structure (D2) and the mean dose (Dmean) both in Gy(E) are given.
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mandibular gland (by 1%), albeit not to a clinically relevant level.
The overall average Dmean and D2 for all OARs and each treatment
modality were plotted in Fig. 2, showing that IMIT resulted in a
lower Dmean in 100% of the cases and IMPT decreased the Dmean
in 86% of the OARs compared to VMAT. For the D2, the respective
numbers were 100% and 59%.
Dosimetric metrics of selected OARs per patient are plotted in
Supplementary Fig. I and II. The maximum dose to the spinal cord
(D2), was significantly reduced (Table 2) for most patients usingIMPT (96%) and for all patients using IMIT (100%) (Supplementary
Fig. II). Regarding Dmean to the oral cavity and D2 of the brainstem,
IMIT decreased doses in all cases, compared to 88% and 96% of the
cases when delivering IMPT. The D2 of the Larynx and mandible
showed less benefit for IMPT and IMIT (28% and 28%, and 50%
and 76%, respectively). For all modalities, radiation doses to the
spinal cord and brainstem remained below the constraints without
the need to underdose the targets (Supplementary Fig. I). For the
mandible 32% (VMAT), 36% (IMPT) and 28% (IMIT) of patients
exceeded the cumulative dose of 120 Gy and the cumulative larynx
392 Re-irradiating HNSCC: benefit of PTconstraint was not met in 78%, 83% and 83% of the patients,
respectively.
The number of patients that benefit from IMPT and/or IMIT over
VMAT was plotted in Fig. 3. All individual patients benefitted from
IMIT with regard to arytenoid, oral cavity, spinal cord, brain stem
and integral dose, as opposed to 80–100% of the patients for IMPT.
The D2 to the bony structures (mandible and vertebrae) decreased
in a low percentage of patients using IMPT (28% and 16%) as com-
pared to a high percentage of patients using IMIT (76% and 84%).
Overall, in this population of re-irradiated HNSCC patients, PT gen-
erated a lower OAR dosage with an advantage of IMIT over IMPT
compared to VMAT (84% and 60% respectively).Discussion
In this ROCOCO in silico clinical trial, through a comparison of
state-of-the-art treatment plans prepared according to a strict clin-
ical protocol, we have demonstrated, that re-RT of HNSCC patients
using PT (IMPT and IMIT) can result in improved sparing of OAR
when compared to photon therapy (VMAT). In most of the cases,
this benefit was greater for the IMIT than for IMPT, which could
be due to different beam characteristics such as sharper lateral
penumbra or different spot size. Whilst the clinical outcome data
from randomised trials comparing proton versus carbon ion treat-
ment are not yet available, several treatment planning studies
are in line with our findings suggesting advantages of carbon ions
in terms of conformity, i.e., dose to the normal tissue [40,41].
However, there are confounding factors that may have influ-
enced our findings. In this ROCOCO study, the treatment plans of
all the modalities were prepared independently complying with
the internal protocols applied in the individual institute’s routine
clinical practice. Therefore, beyond the contouring and planning
goal specifications, the treatment planning procedures themselves
were not necessarily alike. As a result, differences may affect the
numerical outcome reported here. For instance, the different PTV
margins used by the three centres for the different treatment
modalities may have caused an underestimation of the value of
IMPT for re-irradiating HNSCC for the numerical comparison was
unfavourable. These different PTV margins may have arisen from
different choices regarding the range uncertainties (see Material
and Methods). Even though beyond the scope of this publication
a subsequent study with predefined strict margin may shed addi-
tional light on this matter.
Also the influence of different beam angles or optimisation cri-
teria cannot be excluded. For carbon ion plans, full beam direction
flexibility afforded by the gantry was exploited in the beam setups
when deemed advantageous. This decision was taken at the design
stage of this in silico trial and had two main reasons. In clinical rou-
tine, each of the 10 carbon ion centres currently in operation has
some, often (almost) unique, limitations that start to be overcome
with additional degrees of freedom by couch roll and/or pitch
(www.ptcog.ch). Moreover, there are on-going efforts aiming at
making gantries more available. However, research to assess the
actual benefit of gantry versus fixed nozzle is warranted.
Should we all change our strategy to carbon ions then in the set-
ting of recurrent HNSCC eligible for radical re-irradiation? We
know that there have been many years of experience in using pro-
ton beams in daily clinical practice [40,42]. However, for carbon
ion beams there is only little experience, with only three papers
describing clinical data on the treatment of HNSCC either as single
modality or combined with photons/protons[43–45].
In this study, IMPT and IMIT plans using multi-field optimisa-
tion and active scanning delivery were investigated owing to their
superior delivered dose conformity. Using passive-scattering pro-
ton therapy (PSPT) would have altered the results, e.g., Kase et al.[46] compared PSPT with IMPT in different primary tumour sites
including nasal cavity and demonstrated that IMPT resulted in
lower doses to OARs. In general, multi-field optimisation offers
superior OAR sparing compared with PSPT or pencil beam plans
optimised with uniform dose per field, and this benefit can be
essential in the context of re-treatment [25,32].
Due to the sensitivity of pencil beam scanning proton plans to
setup and range uncertainties as well as the degenerate optimal
spot map solutions influenced by optimisation algorithms which
result in varying degrees of plan robustness, it is critical to examine
robustness of PT plans [47]. On the other hand, optimisation algo-
rithms that explicitly incorporate robustness and can reduce
uncertainties in IMPT and IMIT plans are likely to lead to less mod-
ulated fields, hence resembling SFO approach [48]. The influence of
changing anatomy due to tumour regression and weight loss plays
a more significant role in PT than in photon therapy which may
necessitate the use of more frequent imaging or even adaptive
planning strategies [49–53]. Furthermore, the presence of metal
or/and associated artefacts within the treatment beam poses a
problem in PT and is argued to be a patient exclusion criterion.
Therefore, in our study, these artefacts were delineated and over-
ridden to teeth and water densities, respectively, simulating their
absence. This approach carries intrinsic uncertainties, which were
assumed to be negligible with respect to influencing key dosimet-
ric parameters. Richard et al. [54] found that in 110 oral cavity/
oropharynx radiation treatment plans artefacts were identified in
74% obscuring the CTV in 95% of these cases. In a constructed head
and neck phantom, they measured PTV baseline dose ranges of 98–
106% and in the presence of metal amalgam 66–111%. A potential
solution may be exchanging metal fillings by composite before
proton treatment planning to improve tumour visualisation and
dosimetry [54].
An individualised radiation oncology strategy based on multi-
factorial decision support systems would be of great help and is
currently being developed for different tumour types [55–59]. In
this ROCOCO trial, PT is beneficial for sparing OARs in all HNSCC
patients who are candidates for re-RT. However, as long as particle
therapy availability is limited and comes at significantly higher
costs, finding the patient who is benefitting most is highly relevant
to the treating physicians as well as health insurance companies
[60]. Therefore, in the prospective Dutch model-based approach,
a plan comparison is compulsory for all non-standard indications
showing that a reduction in late toxicity computed from a dose dif-
ference will actually result in clinically significant lower normal
tissue complication probability (NTCP) [62]. This potential benefit,
however, must be proven in clinical studies since toxicity is of
course dependent on type of tissue, previous dose, interval and
co-morbidity (e.g., vascular and metabolic comorbidity). In order
to estimate this, a validated NTCP model for re-RT is needed. Devel-
oping such a re-RT-NTCP model will be difficult for it has to take
into account various additional parameters: e.g., interval between
treatments, repair capacity of the tissue as a function of dose given
at first treatment and other treatments between radiations, con-
comitant systemic therapy (not taken into account in the current
study).
In summary, the results of this in silico trial have demonstrated
that PT can significantly reduce the dose to OARs whilst maintain-
ing the prescription dose (assuming the planned dose is represen-
tative of the delivered dose); nevertheless, the exact magnitude of
the clinical benefit is uncertain as a decrease in dose does not
always translate into a clinically relevant decrease of toxicity risk.
Proper development and validation of NTCP models for particle
therapy are by no means trivial as there are many uncertainties
to contend with, e.g., treatment planning, treatment delivery,
relative biological effects, tumour shrinkage, and patient
co-morbidities. Rapid-learning approaches along with prospective
D.B.P. Eekers et al. / Radiotherapy and Oncology 121 (2016) 387–394 393cohort studies as well as (in silico) randomised controlled trials
provide possible solutions in this regard [61].Conflicts of interest statement
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